[Analysis of genes related to sensitivity to navalbine and docetaxel in 10 lung cancer cell lines].
OBJECTIVE
To analyze the drug-sensitivity-related genes to anti-tumor drugs navalbine (NVB) and docetaxel (Doc) in four SCLC and six NSCLC cell lines.


METHODS
The sensitivity of 4 SCLC lines and 6 NSCLC lines to NVB and to Doc was determined with MTT test. The expression of 1291 anti-tumor drug sensitivity-related genes in the 10 cell lines was assayed by cDNA macroarray technique, and cluster analysis was performed to find the relationship between the results obtained by the above mentioned two measurements.


RESULTS
(1) The anti-tumor effect of NVB on the 10 cell lines was apparently better than that of Doc. (2) The drug sensitivity-related genes in these 10 cell lines showed a more close positive correlation with Doc than that with NVB, whereas more genes showed negative correlation with NVB than that with Doc. But in 6 NSCLC cell lines, more genes showed the same positive or negative correlation with the two drugs. (3) 51 genes in the 10 cell lines showed correlation with Doc or NVB. 13 of them had negative correlation with Doc, 11 of them showed positive correlation. 24 of them showed negative correlation with NVB, 3 of them showed positive correlation. 67 genes in 6 NSCLC cell lines showed a correlation with sensitivity to Doc or NVB, among them 34 had negative correlation with Doc, 4 had positive correlation. 25 genes had negative correlation with NVB, 4 had positive correlation. (4) Rab 1, Rab 3, Rho B, Rho C, Rac 1, Rac 2, Gho GDI beta, CD44, integrin alpha5, integrin alpha6, integrin beta5, vinculin showed to be cytoskeleton-related genes differently expressing in SCLC or NSCLC cell lines.


CONCLUSIONS
There is obvious difference in the drug sensitivity-related genes to NVB or Doc between SCLC and NSCLC cell lines.
Cai
Li
L
Department of Internal Medicine, the Third Hospital of Harbin Medical University, Harbin 150040, China.
Li
Jian-hua
JH
Xin
Yan
Y
Niu
Lin-lin
LL
Zang
Jia-lan
JL
Sui
Guang-jie
GJ
D000970:Antineoplastic Agents / Q000494:pharmacology*; D045744:Cell Line, Tumor; D016000:Cluster Analysis; D003598:Cytoskeletal Proteins / Q000378:metabolism; D003599:Cytoskeleton / Q000235:genetics; D000077143:Docetaxel; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D039482:Integrin alpha5 / Q000378:metabolism; D008175:Lung Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D020411:Oligonucleotide Array Sequence Analysis; D043823:Taxoids / Q000494:pharmacology*; D014747:Vinblastine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000077235:Vinorelbine; D020761:rab1 GTP-Binding Proteins / Q000378:metabolism; D020830:rac1 GTP-Binding Protein / Q000378:metabolism
D000970:Antineoplastic Agents; D003598:Cytoskeletal Proteins; D039482:Integrin alpha5; D043823:Taxoids; D000077143:Docetaxel; D014747:Vinblastine; D020761:rab1 GTP-Binding Proteins; D020830:rac1 GTP-Binding Protein; D000077235:Vinorelbine